Onward Ho: Biocon Signals Glargine Build Up, US Biosimilars Pricing ‘Sanity’
Also Addresses Insulin Aspart CRL From FDA On Rival To NovoLog
Executive Summary
Biocon anticipates significant US uptake of its Viatris-partnered interchangeable insulin glargine biosimilar on the back of commercial arrangements in place and expects to "move the market" in 2022. All eyes are also on the trajectory of biosimilar insulin aspart, which received a CRL from the US FDA.
You may also be interested in...
Biocon Joins Fray For Denosumab, Ustekinumab Biosimilars
Biocon is progressing trials for biosimilar rivals to Amgen’s Prolia/Xgeva (denosumab) and J&J’s Stelara (ustekinumab), even as it gears for other large opportunities coming its way via the Viatris deal including for blockbusters Humira and Eylea.
Biocon Finalizes Merger Between Covidshield And Biologics Business
The merger between Serum Institute of India subsidiary Covidshield Technologies and Biocon Biologics has finally completed, subject to requisite approvals, after a Biocon board meeting.
Biocon And Viatris Get CRL From FDA On Insulin Aspart
Viatris and partner Biocon have suffered a setback over their proposed insulin aspart biosimilar rival to NovoLog in the US, after the FDA issued a CRL relating to the filing.